CAPTRUST Financial Advisors
PVCT

CAPTRUST Financial Advisors’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

CAPTRUST Financial Advisors’s Portfolio PVCT Stock Details PVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-57,659
Closed -$3K – 4662
2022
Q2 		$3K Buy
57,659
+37,257
+183% +$1.94K ﹤0.01% 4389
2022
Q1 		$1K Sell
20,402
-22,257
-52% -$1.09K ﹤0.01% 4835
2021
Q4 		$2K Buy
42,659
+20,202
+90% +$947 ﹤0.01% 4495
2021
Q3 		$1K Hold
22,457
– – ﹤0.01% 4557
2021
Q2 		$2K Hold
22,457
– – ﹤0.01% 4256
2021
Q1 		$2K Hold
22,457
– – ﹤0.01% 4119
2020
Q4 		$1K Buy
+22,457
New +$1K ﹤0.01% 3361
2020
Q3 		– Sell
-21,657
Closed -$1K – 3396
2020
Q2 		$1K Buy
+21,657
New +$1K ﹤0.01% 2793

Other funds holding PVCT

HFBOT
Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
LDB
Lee, Danner & Bass Nashville, Tennessee $1.73B AUM 36.69% 1-Year Est. Return
ACM
Academy Capital Management Waco, Texas $699M AUM 12.08% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
LIA
LBMC Investment Advisors Brentwood, Tennessee $1.64B AUM 15.26% 1-Year Est. Return

CAPTRUST Financial Advisors's PVCT Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q3 2022, closing a stake of 57,659 shares — an estimated $3K sold.

CAPTRUST Financial Advisors first reported a position in PVCT in Q2 2020 and held it in 8 quarters. The position peaked at $3K in Q2 2022. 7 funds tracked by Wall St. Rank hold PVCT as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 57,659 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q3 2022, an estimated $3K.
  • CAPTRUST Financial Advisors first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2020 and held it in 8 quarters.
  • CAPTRUST Financial Advisors's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $3K in Q2 2022.
  • 7 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.